Highest percentage of patients with HBsAg loss after end of treatment for those receiving xalnesiran + immunomodulator ...

Veligrotug is an investigational monoclonal antibody that inhibits the activity of insulin-like growth factor-1 receptor.

The approval was based on data from 2 randomized, double-blind, placebo-controlled trials, ARCADIA 1 and ARCADIA 2.

The approval was based on phase 3 data from the randomized, double-blind, placebo-controlled CAHtalyst adult study and CAHtalyst pediatric study.

ACIP recommends extending interval for two-dose series and adding three-dose series in accordance with FDA label ...

The Breakthrough Therapy designation is supported by data from the randomized, open-label phase 2 SOLSTICE trial.

The Food and Drug Administration (FDA) has approved Unloxcyt™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) ...

The Breakthrough Therapy designation is supported by data from the randomized, double-blind phase 3 HERCULES trial.

The sBLA submission included results from the randomized, parallel-arm, placebo-controlled and active-controlled trial foresiGHt.

Compared with placebo, obicetrapib lowered LDL-C by 33% at day 84 ( P <.0001). Changes in other biomarkers, including high-density lipoprotein cholesterol (HDL-C), non-HDL-C, lipoprotein (a), ...

After the initiation of an AID system, glycemic control improved and the effect persisted throughout the study period. (HealthDay News) — Initiation of an automated insulin delivery (AID) system ...